Yulzety Patent Expiration

Yulzety is a drug owned by Rosemont Pharmaceuticals Holdings Inc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 06, 2044. Details of Yulzety's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12648950 Oral Liquid Formulation Of Rivaroxaban
Aug, 2044

(17 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Yulzety is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Yulzety's family patents as well as insights into ongoing legal events on those patents.

Yulzety's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Clinical Trials

Recent Clinical Trials on Yulzety:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Yulzety(Rivaroxaban) has 1 clinical trial that has been verified in 2024.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions The Affiliated Hospital of Qingdao University NA COMPLETED
(Sep 1, 2026)
PHASE1
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease Regeneron Pharmaceuticals NA RECRUITING
(Aug 1, 2026)
PHASE3
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients University Hospital, Tours NA RECRUITING
(Jun 1, 2026)
PHASE3
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing University Hospital, Angers NA RECRUITING
(Jun 1, 2026)
PHASE3
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain. Rennes University Hospital NA RECRUITING
(Jun 1, 2026)
PHASE3
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome University College, London NA COMPLETED
(May 1, 2026)
PHASE2
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin VarmX B.V. NA COMPLETED
(May 1, 2026)
PHASE1
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation Massachusetts General Hospital NA COMPLETED
(Apr 1, 2026)
PHASE3
Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease The George Institute NA COMPLETED
(Mar 1, 2026)
PHASE3
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma Lawson Health Research Institute The Ottawa Hospital, Dalhousie University, Niagara Health System, Hamilton Health Sciences Corporation ACTIVE NOT RECRUITING
(Feb, 2024)
PHASE2, PHASE3
INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority Population Health Research Institute University of Cape Town WITHDRAWN
(Jul, 2022)
PHASE3
Alexa, What is Eliquis and Xarelto? Cedars-Sinai Medical Center NA TERMINATED
(Mar, 2022)
NA
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. Fadoi Foundation, Italy University Of Perugia COMPLETED
(Feb, 2022)
PHASE3
Reveal Transition - A Mechanistic Study in Transition / Stabilized Phase of CAD University Hospital Tuebingen Bayer WITHDRAWN
(Jun, 2019)
Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury Swiss Paraplegic Research, Nottwil NA WITHDRAWN
(Jan, 2019)
PHASE4
Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions Bayer Janssen Research & Development, LLC COMPLETED
(Jun, 2015)
PHASE1
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Bayer COMPLETED
(Aug, 2014)
PHASE3
Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation Tohoku University NA UNKNOWN
(May, 2014)
Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban Assistance Publique - Hôpitaux de Paris NA COMPLETED
(Mar, 2011)
PHASE2, PHASE3




Generic Launch

Generic Release Date:

Yulzety's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 06, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Yulzety Generic API suppliers:

Rivaroxaban is the generic name for the brand Yulzety. 21 different companies have already filed for the generic of Yulzety, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Yulzety's generic

Alternative Brands for Yulzety

There are several other brand drugs using the same active ingredient (Rivaroxaban) as Yulzety. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Janssen Pharms
Xarelto


Apart from brand drugs containing the same ingredient, some generics have also been filed for Rivaroxaban, Yulzety's active ingredient. Check the complete list of approved generic manufacturers for Yulzety





About Yulzety

Yulzety is a drug owned by Rosemont Pharmaceuticals Holdings Inc. Yulzety uses Rivaroxaban as an active ingredient. Yulzety was launched by Rosemont in 2026.

Approval Date:

Yulzety was approved by FDA for market use on 16 October, 2026.

Active Ingredient:

Yulzety uses Rivaroxaban as the active ingredient. Check out other Drugs and Companies using Rivaroxaban ingredient

Dosage:

Yulzety is available in suspension form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
4MG/ML SUSPENSION Prescription ORAL
2MG/ML SUSPENSION Prescription ORAL